Table 2.
Characteristics of Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Individuals Within 6 Months of Diagnosis of Hepatocellular Carcinoma or Other Liver Event or Within 6 Months of End of Follow-Up in the Remaining Cohort
| Characteristic | No HCC or Other Liver Event (n = 6787) | HCC (n = 72) | Other Liver Event (n = 375) |
|---|---|---|---|
| Age, years, median (IQR) | 44.8 (37.6, 50.8) | 49.6 (46.0, 55.8) | 43.9 (38.6, 49.6) |
| Follow-up time, years, median (IQR) | 5.3 (2.5, 9.7) | 6.0 (2.4, 9.2) | 3.9 (1.6, 6.7) |
| Female sex, N (%) | 2182 (32.1) | 17 (23.6) | 106 (28.3) |
| White race, N (%) | 6124 (90.2) | 68 (94.4) | 343 (91.5) |
| Region, N (%) | |||
| Western Europe | 3882 (57.2) | 55 (76.4) | 266 (70.9) |
| Eastern Europe /Argentina | 1898 (28.0) | 6 (8.3) | 73 (19.5) |
| Canada | 1007 (14.8) | 11 (15.3) | 36 (9.6) |
| HIV risk group, N (%) | |||
| Men who have sex with men | 802 (11.8) | 6 (8.3) | 27 (7.2) |
| Injection drug use | 4003 (59.0) | 40 (55.6) | 249 (66.4) |
| Heterosexual | 1129 (16.6) | 17 (23.6) | 43 (11.5) |
| Other/unknown | 853 (12.6) | 9 (12.5) | 56 (14.9) |
| Body mass index category, N (%)a | |||
| Underweight | 179 (6.8) | 3 (12.0) | 23 (13.9) |
| Normal weight | 1794 (68.6) | 17 (68.0) | 109 (65.7) |
| Overweight | 527 (20.2) | 4 (16.0) | 27 (16.3) |
| Obese | 115 (4.4) | 1 (4.0) | 7 (4.2) |
| Ever smoked, N (%)b | 2987 (80.1) | 25 (75.8) | 180 (86.5) |
| Ever abused alcohol, N (%)c | 610 (18.6) | 4 (20.0) | 22 (30.6) |
| Diabetes mellitus, N (%) | 313 (4.6) | 6 (8.3) | 29 (7.7) |
| HBV coinfection, N (%)d | 292 (4.5) | 6 (8.3) | 23 (6.3) |
| Ever HBV active drugs, N (%) | 2633 (38.8) | 34 (47.2) | 136 (36.3) |
| Ever hepatitis C virus active drugs, N (%) | 1537 (14.6) | 23 (31.9) | 68 (18.1) |
| Ever combination antiretroviral therapy, N (%) | 5964 (87.9) | 71 (98.6) | 340 (90.7) |
| Ever AIDS, N (%) | 2163 (31.9) | 28 (38.9) | 167 (44.5) |
| Detectable HIV RNA, N (%)e | 1189 (25.1) | 9 (15.5) | 123 (38.4) |
| CD4 cell count current, cells/mm3, median (IQR)f | 470 (289, 670) | 286 (201, 438) | 242 (110, 397) |
| Cirrhosis, N (%)g | 1447 (25.0) | 45 (75.4) | 189 (69.7) |
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; IQR, interquartile range.
a Body mass index was categorized in 2615 individuals without an event, 25 individuals with HCC, and 166 individuals with other liver events.
b Smoking status was determined in 3728 individuals without an event, 33 individuals with HCC, and 208 individuals with other liver events.
c Alcohol abuse was determined in 3278 individuals without an event, 20 individuals with HCC, and 72 individuals with other liver events.
d HBV coinfection was determined in 6489 individuals without an event, 69 individuals with HCC, and 366 individuals with other liver events.
e Detectable HIV RNA was determined in 4746 individuals without an event, 58 individuals with HCC, and 320 individuals with other liver events.
f CD4 cell count current was determined in 6254 individuals without an event, 69 individuals with HCC, and 349 individuals with other liver events.
g Cirrhosis was determined in 5799 individuals without an event, 61 individuals with HCC, and 271 individuals with other liver events.